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Objectives The aim of this study was to provide the spectrum and prevalence of mutations in the 12 Brugada syndrome
(BrS)–susceptibility genes discovered to date in a single large cohort of unrelated BrS patients.
Background BrS is a potentially lethal heritable arrhythmia syndrome diagnosed electrocardiographically by coved-type ST-
segment elevation in the right precordial leads (V1 to V3; type 1 Brugada electrocardiographic [ECG] pattern) and
the presence of a personal/family history of cardiac events.
Methods Using polymerase chain reaction, denaturing high-performance liquid chromatography, and DNA sequencing,
comprehensive mutational analysis of BrS1- through BrS12-susceptibility genes was performed in 129 unrelated
patients with possible/probable BrS (46 with clinically diagnosed BrS [ECG pattern plus personal/family history
of a cardiac event] and 83 with a type 1 BrS ECG pattern only).
Results Overall, 27 patients (21%) had a putative pathogenic mutation, absent in 1,400 Caucasian reference alleles, includ-
ing 21 patients with an SCN5Amutation, 2 with a CACNB2Bmutation, and 1 each with a KCNJ8mutation, a KCND3
mutation, an SCN1Bbmutation, and an HCN4mutation. The overall mutation yield was 23% in the type 1 BrS ECG
pattern-only patients versus 17% in the clinically diagnosed BrS patients and was significantly greater among young
men 20 years of age with clinically diagnosed BrS and among patients who had a prolonged PQ interval.
Conclusions We identified putative pathogenic mutations in 20% of our BrS cohort, with BrS genes 2 through 12 account-
ing for 5%. Importantly, the yield was similar between patients with only a type 1 BrS ECG pattern and those
with clinically established BrS. The yield approaches 40% for SCN5A-mediated BrS (BrS1) when the PQ interval
exceeds 200 ms. Calcium channel–mediated BrS is extremely unlikely in the absence of a short QT interval.
(J Am Coll Cardiol 2012;60:1410–8) © 2012 by the American College of Cardiology Foundation
Published by Elsevier Inc. http://dx.doi.org/10.1016/j.jacc.2012.04.037sBrugada syndrome (BrS) is a rare heritable arrhythmia
syndrome associated with an increased risk of sudden
cardiac death (SCD) secondary to re-entrant polymorphic
ventricular tachycardia and ventricular fibrillation (1). The
iagnosis of BrS is based on the presence of coved-type ST-
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October 9, 2012:1410–8 Brugada Syndrome–Associated Mutationspattern, in the absence of structural heart disease or pharma-
cological agents known to cause a Brugada-like ECG pattern
(www.brugadadrugs.org). Additionally, to make a proper di-
agnosis, the diagnostic ECG pattern should be present to-
gether with either personal symptoms, family history of pre-
mature SCD, or at least 1 additional relative with a positive
type 1 Brugada ECG pattern (2). Due to the transient and
dynamic nature of the Brugada ECG pattern, administration
of sodium channel blockers (e.g., ajmaline, flecainide, procain-
amide) are used to unmask the type 1 ECG pattern (2). In
eneral, BrS is understood as a disorder that affects young
ale adults with an arrhythmogenic manifestation first
ccurring in the fourth decade of life with sudden death
sually occurring during sleep (3,4). However, BrS may also
anifest in the young and during infancy, and, when
amilial, BrS is inherited as an autosomal dominant trait;
owever, more than half may be sporadic in nature (5).
Over the past 20 years, 12 BrS-susceptibility genes (BrS1
hrough BrS12) have been identified. Loss-of-function
utations in the SCN5A-encoded -subunit of the cardiac
sodium channel (Nav1.5) represents the most common
genetic substrate for BrS (annotated as type 1 BrS or BrS1),
accounting for 15% to 30% of the disorder (5–7). In
addition to sodium channel dysfunction, mutations involv-
ing the L-type calcium channel alpha1 (1), beta2 (2), and
alpha2delta (2) subunits encoded by CACNA1C (8),
CACNB2B (8) and CACNA2D1 (9), respectively, may cause
10% to 15% of BrS (9).
Over the past 5 years, 8 of the 12 BrS-susceptibility genes have
been identified in which mutations result in: 1) a reduction of the
cardiac sodium channel (INa) current (GPD1L [10], SCN1B [11],
ncluding the alternatively spliced exon 3A, SCN1Bb [12], SCN3B
13], and MOG1 [14]); 2) an increase in the transient outward
otassium (Ito) current (KCNE3 [15], and KCND3 [16]); 3) an
ncrease in the IKATP current (KCNJ8) (17); or 4) a reduction of
he pacemaker (If) current (HCN4) (18).
Although the relative contribution of SCN5A to BrS has
been well characterized by several investigating laboratories
(19), the molecular genetic contribution of the 12 BrS-
susceptibility genes has not been systematically analyzed in
a single large cohort of unrelated BrS patients.
In 2011, 2 expert consensus documents were published
on the use of genetic testing in the clinical evaluation of
cardiac channelopathies and cardiomyopathies (20,21). Al-
though the Heart Rhythm Society (HRS)/European Heart
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edical, Inc., and Transgenomic. Intellectual property derived from Dr. Ackerman’s
esearch program resulted in license agreements in 2004 between Mayo Clinic Health
olutions (formerly Mayo Medical Ventures) and PGxHealth (formerly Genaissance
harmaceuticals, now recently acquired by Transgenomic). All other authors have
eported that they have no relationships relevant to the contents of this paper to
isclose. This work was supported by the Mayo Clinic Windland Smith Rice
omprehensive Sudden Cardiac Death Program. Mr. Giudicessi was supported by a
ational Heart, Lung, and Blood Institute Kirschstein NRSA Individual Predoctoral
D/PHD Fellowship (F30-HL106993). The first 2 authors contributed equally tothis work.
Manuscript received March 5, 2012; accepted April 4, 2012.Rhythm Association (EHRA)
Expert Consensus Statement
(21) recommended genetic test-
ing for patients with a clinical
diagnosis of BrS, the Canadian
Cardiovascular Society (CCS)/
Canadian Heart Rhythm Society
(CHRS) joint position paper
(20) also advised genetic testing
even in the setting of an isolated
type 1 Brugada ECG pattern.
In the present study, we pro-
vide the spectrum and prevalence
of BrS1 through BrS12 associ-
ated gene mutations discovered
in a large cohort of BrS patients.
Furthermore, through the assessment of the genetic testing
yield for 46 patients with clinically diagnosed BrS and for 83
unrelated patients with only a type 1 Brugada ECG pattern,
we provide, for the first time, concrete data to further guide
genetic testing recommendations for these 2 patient
populations.
Methods
Study population. The study population consisted of 46
unrelated patients with clinically diagnosed BrS and 83
unrelated patients having either a spontaneous or drug-
induced type 1 Brugada ECG pattern as their sole finding
who were referred to either the Windland Smith Rice
Sudden Death Genomics Laboratory at the Mayo Clinic,
Rochester, Minnesota, or to the Molecular Cardiology
Laboratory, La Fondazione IRCCS Policlinico San Matteo
di Pavia, Pavia, Italy, for genetic testing. A clinical diagnosis
of BrS was made using the strict criteria provided in the
Consensus Conference Document (2). Briefly, a clinical
diagnosis of BrS was assigned to an individual presenting
with a diagnostic type 1 Brugada ECG pattern (coved-type
ST-segment elevation in the right precordial V1 to V3 leads)
either spontaneously and/or after intravenous injection of a
sodium channel blocking agent (ajmaline, flecainide, or
procainamide) and either a personal or family history of
arrhythmic syncope, cardiac arrest, or SCD. Patients with
an acquired cause of a type 1 ECG pattern were excluded.
Patients reporting palpitations, atypical chest pain, and/or a
history of syncope with clinical characteristics strongly
suggestive of vasovagal syncope were considered asymptom-
atic. This study was approved by both the Mayo Foundation
Institutional Review Board and the Medical Ethical Com-
mittee of La Fondazione IRCCS Policlinico San Matteo di
Pavia. Informed consent was obtained from all patients.
ECG analysis. The 12-lead electrocardiograms were re-
corded at baseline at a paper speed of 25 mm/s. The P-wave
duration and PR, QRS, and QT intervals were measured
manually from basal electrocardiograms, and the QTc
Abbreviations
and Acronyms
BrS  Brugada syndrome
CCS  Canadian
Cardiovascular Society
CHRS  Canadian Heart
Rhythm Society
ECG  electrocardiographic
EHRA  European Heart
Rhythm Association
HRS  Heart Rhythm
Society
SCD  sudden cardiac
deathinterval was calculated according to Bazett’s formula. The
C
s
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Brugada Syndrome–Associated Mutations October 9, 2012:1410–8presence of a spontaneous type 1 Brugada ECG pattern was
evaluated both on basal electrocardiograms and 12-lead
24-h Holter recordings.
Mutational analysis. After receiving informed consent, a
comprehensive open reading frame/splice site mutational
analysis of all amino acid coding exons and intron borders of
the 12 BrS-susceptibility genes (SCN5A, GPD1L,
ACNA1C, CACNB2B, SCN1B [including the alternatively
pliced exon 3A; SCN1Bb], SCN3B, KCNE3, KCNJ8, KCND3,
CACNA2D1, MOG1, and HCN4) was performed using
polymerase chain reaction, denaturing high-performance
liquid chromatography, and DNA sequencing, as previously
described (22). Polymerase chain reaction primer sequences
and polymerase chain reaction/denaturing high-performance liq-
uid chromatography conditions are provided in Online
Tables 1 to 13.
To be considered a putative pathogenic mutation, the
genetic variant had to be: 1) a nonsynonymous variant; and
2) absent in at least 700 ethnically matched controls
(1,400 reference alleles) plus all available online databases,
including the 1000 Human Genome Project database (23).
Control genomic DNA was obtained from the European
Collection of Cell Cultures (HPA Culture Collections,
Salisbury, United Kingdom), the Human Genetic Cell
Repository sponsored by the National Institute of General
Medical Sciences and the Coriell Institute for Medical
Research (Camden, New Jersey), and the Blood Transfu-
sional Center at La Fondazione IRCCS Policlinico San
Matteo di Pavia (Pavia, Italy).
Demographics of Unrelated Patients Referred foTable 1 Demographics of Unrelated Patient
Patient demographics
No. of probands
Age at diagnosis, yrs
Range
Males
Females
Average QTc interval, ms 4
Average PQ interval, ms 1
Symptomatic patients
Family history of cardiac events/
unexplained sudden death
Type 1 ST-segment elevation at baseline
Type 1 ST-segment elevation with sodium blockade
Mutation detection yield
Total yield
Males
Females
SCN5A positive
PQ interval, ms 1
Values are n, mean SD, or n (%). *Clinically diagnosed BrS includes p
in the right precordial V1 to V3 leads) present either spontaneously and
flecainide, or procainamide) with either a personal and/or family history of a
BrS  Brugada syndrome; ECG  electrocardiographic.Mutations were annotated using the single-letter nomen-
clature in which F892I, for example, denotes a nonsynony-
mous single nucleotide substitution producing a missense
mutation, whereby the wild-type amino acid phenylalanine
(F) has been replaced by an isoleucine (I) at amino acid 892.
Statistical analysis. Comparisons of groups identified on
the basis of the clinical characteristics and genotype were
performed by univariate analysis. The Student t test was
used for continuous variables. The Fisher exact test was used
for categorical variables and odds ratios for unadjusted data,
and their 95% confidence intervals were calculated. Contin-
uous variables are presented as mean  SD. A 2-sided
p value 0.05 was considered statistically significant.
GraphPad Prism 3.02 was used for statistical analysis.
Results
Study population. Table 1 summarizes the clinical demo-
graphics of the 129 unrelated patients referred for
laboratory-based BrS genetic testing. The majority of pa-
tients were male (n  104, 81%) and of Caucasian descent
(n  122, 95%) with a mean age at diagnosis of 43  14
years. Sixteen patients (12%) experienced cardiac events,
including 6 (4.6%) with documented aborted cardiac arrest/
SCD. A type 1 Brugada ECG pattern (Fig. 1) was present
spontaneously in 61 patients (47%), was induced only with
a sodium channel blocker in 61 patients (47%) and appeared
during fever in the remaining 7 patients. Among those with
a spontaneous type 1 ECG pattern, the diagnostic electro-
cardiogram was not evident in 18% at the time of the
Genetic Testingerred for BrS Genetic Testing
all
Patients With Clinically
Diagnosed* BrS
Patients With Type
1 Brugada ECG
Pattern Only
46 83
14 43 15 42 14
1 10–81 8–74
81) 28 (61) 76 (92)
19) 18 (39) 7 (8)
27 410 27 409 27
29 177 28 170 30
12) 16 (35) 0 (0)
29) 37 (80) 0 (0)
47) 30 (65) 31 (37)
53) 16 (35) 52 (63)
21) 8 (17) 19 (23)
19) 8 (29) 12 (16)
28) 0 (0) 7 (100)
16) 6 (13) 15 (18)
31 199 32 188 31
with a type 1 Brugada ECG pattern (coved-type ST-segment elevation
r intravenous injection of a sodium channel blocking agent (ajmaline,r BrSs Ref
Over
129
43
8–8
104 (
25 (
09
72
16 (
37 (
61 (
68 (
27 (
20 (
7 (
21 (
91
atients
/or afterrhythmic syncope, cardiac arrest, or sudden cardiac death.
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October 9, 2012:1410–8 Brugada Syndrome–Associated Mutationsdiagnosis but only during follow-up visits (follow-up, 24 
14 months). A strict clinical diagnosis of BrS was assigned
to 46 patients (28 male patients, average age at diagnosis of
43  15 years, 30 with a spontaneous type 1 ECG pattern,
14 with a drug-induced type 1 ECG pattern, and 2 with a
spontaneous ECG pattern during fever; 16 were symptom-
atic, and 37 had a positive family history of cardiac events).
Eighty-three asymptomatic patients (77 male patients, average
age, 42  14 years) with no family history were referred for
genetic testing solely due to the patient’s idiopathic type 1
Brugada ECG pattern that occurred either spontaneously (31
cases) or after intravenous injection of a sodium channel
blocker (n  47) or during fever (n  5).
Mutational analysis. PUTATIVE PATHOGENIC MUTATIONS.
Overall, 27 putative pathogenic mutations (21 SCN5A,
2 CACNB2B, 1 KCNJ8, 1 KCND3, 1 SCN1Bb, and 1
HCN4) were identified in 27 of 129 unrelated BrS patients
(21%; 20 male, 7 female) (Table 2). Each mutation was
absent in not only 1,400 ethnicity-matched reference
alleles but also in all publicly available databases including
the 1000 Human Genome Project (23).
Of the 21 SCN5A mutations, 8 were “radical” mutations
5 nonsense and 2 insertion/deletion frameshift mutations,
nd 1 splice site mutation) 12 were missense mutations
ocalizing to the N-terminus (n  1), the transmembrane
panning region (n  1, IS1 through IS4; n  3, IIS1
through S4; n  3, IIIS1 through S4; or n  1, IVS1
through S4), the linker domain (n 2, DIII through DIV),
r the C-terminus (n  1), and 1 was an in-frame deletion
Fig. 2). However, it must be recognized that nearly 2% of healthy
aucasians and 4% of seemingly healthy non-Caucasians also host
issense SCN5A variants, leading to a potential conundrum in the
Figure 1 Diagnostic Brugada Syndrome Electrocardiogram
Representative electrocardiographic (ECG) traces of a type 1 Brugada ECG pat-
tern not present in basal conditions (A), but appearing during Holter recording
(B) in a 56-year-old man.nterpretation of the genetic test results (24). dImportantly, none of the Nav1.5 missense mutations
resided in low probability of pathogenicity regions of the
channel (i.e., DI through DII or DII through DIII linker
regions), where the vast majority of rare variants identified in
healthy control populations reside (25). Instead, 5 of 12 (42%)
SCN5A missense mutations resided in the critical pore-
forming or S4 voltage-sensing regions of Nav1.5. Putative
pathogenic mutations in all other genes (CACNB2B, KCNJ8,
KCND3, SCN1B, and HCN4) were missense mutations.
Although 21 patients (16.3%) hosted SCN5A mutations
overall, only 6 patients (4.6%) were identified with a
mutation in 1 of the 11 other BrS-susceptibility genes
(Table 2). Two patients (1.5%) were identified with a
mutation in an auxiliary L-type calcium channel subunit. An
symptomatic 60-year-old Caucasian man, presenting with
spontaneous type 1 ECG pattern, a QTc interval of 428
s, and a positive family history was identified as having
499D-CACNB2B and an asymptomatic 58-year-old
aucasian woman with a spontaneous type 1 ECG pattern,
QTc interval of 447 ms, and a negative family history was
dentified with V340I-CACNB2B. The remaining 4 pa-
ients had 1 of the following mutations: KCNJ8-S422L,
CND3-G600R, SCN1Bb-Q204R, and HCN4-S841L
Table 2). The 2 patients carrying KCNJ8-S422L and
CND3-G600R were described previously, and both mu-
ations conferred a marked gain-of-function to their respec-
ive potassium channel (16,17). No mutations were identi-
ed in KCNE3, SCN3B, GPD1L, or MOG1.
RARE GENETIC VARIANTS. In addition to these aforemen-
tioned putative BrS-associated mutations, 11 uncommon
nonsynonymous genetic variants (present in published and
internal controls with a measurable frequency 0.01% but
1%) were identified in 13 additional patients (Table 3).
even of the 11 rare variants (S216L-SCN5A [26], R1512W-
CN5A [27], R214Q-SCN1Bb [28], S160T-CACNB2B [9]
identified in 2 patients], S709N-CACNA2D1 [9] [2 pa-
ients], S755T-CACNA2D1 [29], and L450F-KCND3 [16])
ave been characterized functionally as electrophysiologically
bnormal and/or associated with BrS or other genetically
ransmitted arrhythmogenic diseases linked to BrS (i.e., short
T syndrome and early repolarization syndrome), suggesting
hat these genetic variants may contribute to the development
f BrS. However, despite their previous implication in these
arious disease states, we chose to be ultraconservative and did
ot consider these variants as disease-causing mutations due to
heir presence in ostensibly healthy controls and therefore
xcluded them from our overall yield and genotype–phenotype
orrelations.
nfluence of phenotype on the mutation detection
ield. To better understand potential phenotypic effects on
he yield of mutational analysis, we further divided our
29-patient cohort into 8 specific phenotypic categories:
) asymptomatic, no family history, spontaneous ECG
attern only (n  31); 2) asymptomatic, no family history,
rug-induced ECG pattern only (n 52); 3) asymptomatic,
f
7
p
d
o
f
f
p
t
o
a
o
e
w
E
w
4
y
t
y
t
n
(
(
s
y
b
t
(
m
y
o
1
t
2
2
i
y
p
y
1414 Crotti et al. JACC Vol. 60, No. 15, 2012
Brugada Syndrome–Associated Mutations October 9, 2012:1410–8positive family history, spontaneous ECG pattern (n  17);
4) asymptomatic, positive family history, drug-induced
ECG pattern only (n  13); 5) symptomatic, no family
history, spontaneous ECG (n  6); 6) symptomatic, no
amily history, drug-induced ECG only (n  3);
) symptomatic, positive family history, spontaneous ECG
attern (n 7); and 8) symptomatic, positive family history,
rug-induced ECG pattern only (n  0). Although the
verall mutation discovery yield was 21%, this yield ranged
rom a low of 0% for those patients with symptoms, no
amily history, and a drug-induced ECG pattern (0 of 3
atients) to as high as 50% for those patients with symp-
oms, no family history, and a spontaneous ECG pattern (3
f 6 patients). However, none of these differences in yield
chieved statistical significance due to the small sample sizes
f each subcategory (Fig. 3). Notably, there was no differ-
nce in mutation detection yield between those patients
ith solely a spontaneous or drug-induced type 1 Brugada
CG pattern (19 of 83 patients, 23%) compared with those
ho fully satisfied the current clinical definition of BrS (8 of
6 patients, 17%, p  0.51) (Table 1).
An interesting effect of age on the mutation detection
Summary of Brugada Syndrome-Associated MutationsTable 2 Summary of Brugada Syndrome-Associated Mutations
Patient # Gene Exon
Nucleotide
Change Mu
Major BrS genotype SCN5A
1 SCN5A 2 80GA R27H
2 SCN5A 2 127CT R43X*
3 SCN5A 4 477 TA Y159X
4 SCN5A 16 2466GT W822C
5 SCN5A 16 2632CT R878C
6 SCN5A 16 2674TA F892I*
7 SCN5A 17 3175CT Q1059
8 SCN5A 17 3175CT Q1059
9 SCN5A 18 3352CT Q1118
10 SCN5A 21 3673GA E1225
11 SCN5A 21 3673GA E1225
12 SCN5A 21 3806AG N1269
13 SCN5A 23 4140CG N1380
14 SCN5A Intron24 42991 GT G1433
15 SCN5A 26 4501CG L1501
16 SCN5A 28 4849-4851delTTC F1617
17 SCN5A 28 4952-4953insT L1650
18 SCN5A 28 5150TC L1717
19 SCN5A 28 5227 GA G1743
20 SCN5A 28 5324delT N1774
21 SCN5A 28 5494CG Q1832
Minor BrS genotypes
22 CACNB2B 10 1018GA V340I*
23 CACNB2B 13 1497GC E499D
24 HCN4 8 2522CT S841L
25 KCND3 7 1798GA G600R
26 KCNJ8 2 1265CT S422L
27 SCN1b 3A 611AG Q204R
*Novel mutation for this cohort.
BrS  Brugada syndrome.ield was observed, especially among male patients. Overall, 2he 20 mutation-positive males were younger (age, 33  15
ears) compared with the 84 mutation-negative male pa-
ients (age, 43  12 years) (p  0.001). However, there was
o real difference in average age between mutation-positive
age, 43  16 years) and mutation-negative female patients
age, 51  17 years) (p  0.34). The overall yield was
ignificantly greater among BrS patients younger than 20
ears of age (6 of 8 patients, 75%) compared with patients
etween 20 and 40 years of age (10 of 46 patients, 22%) and
hose older than 40 years of age (11 of 75 patients, 15%)
p  0.0003) (Fig. 4). This significant difference was even
ore striking when comparing male patients only (20
ears of age [5 of 6 patients], 83%; 20 to 40 years of age [9
f 42 patients], 21%; 40 years of age [6 of 56 patients],
1%) (p  0.0001). The female patient group was too small
o draw any meaningful conclusions (20 years of age [1 of
patients], 50%; 20 to 40 years of age [1 of 4 patients],
4%; 40 years of age [5 of 19 patients], 26%). Interest-
ngly, however, this age effect on the mutation detection
ield was only evident among the 46 clinically certain BrS
atients (20 years of age [4 of 4 patients], 100%; 20 to 40
ears of age [3 of 13 patients], 23%; 40 years of age, [1 of
Mutation
Type Location
Age,
yrs Sex
Symptomatic
(Yes/No)
Family History
(Yes/No)
Missense N-terminal 8 M No No
Nonsense N-terminal 19 M No Yes
Nonsense DI–S2 40 M No No
Missense DI–S4 24 M Yes No
Missense DII–S5/S6 34 M No No
Missense DII–S5/S6 30 F No No
Nonsense DII–DIII 38 M No No
Nonsense DII–DIII 16 M Yes No
Nonsense DII–DIII 51 M No No
Missense DIII–S1 46 F No No
Missense DIII–S1 43 M No No
Missense DIII–S2/S3 53 M No Unknown
Missense DIII–S5/S6 31 M Yes No
Splice DIII–S5/S6 10 M No Yes
Missense DIII–DIV 55 M No No
In-frame del DIV–S3/S4 49 F No No
* Frame shift DIV–S4/S5 16 F No No
Missense DIV–S5/S6 44 M No No
Missense DIV–S5/S6 14 M Yes Yes
* Frame shift DIV–S6 34 M No No
Missense C-terminal 28 M No No
Missense GK domain 58 F No No
Missense C-terminal 60 M No Yes
Missense Cytoplasmic 64 F No No
Missense Cytoplasmic 22 M No Yes
Missense Cytoplasmic 30 M No No
Missense Cytoplasmic 41 F No Notation
*
*
X*
X*
X
K
K
S*
K*
sp
V
del
137X
P*
R
11X
E
*
*
*9 patients], 3%) (p  0.0001) compared with the 83
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October 9, 2012:1410–8 Brugada Syndrome–Associated Mutationsreferral patients with only a type 1 Brugada ECG pattern
(20 years of age [2 of 4 patients], 50%; 20 to 40 years of
age [7 of 33 patients], 21%; 40 years of age [10 of 46
patients], 22%) (p  0.42).
Genotype–phenotype correlations. When comparing
SCN5A mutation–positive patients with those patients who
were SCN5A negative, the PQ interval was significantly
longer (191  31 ms vs. 169  28 ms, p  0.0015). In fact,
an SCN5A mutation was identified in 39% of those with a
PQ interval 200 ms compared with only 8% of those with
a PQ interval 200 ms (odds ratio: 7; 95% CI: 3 to 20; p 
0.0001). For the subset of patients with an isolated, idio-
pathic type 1 ECG pattern only, 38% of the patients with a
PQ interval 200 ms were SCN5A positive compared with
11% with a PQ interval 200 ms (OR: 8; 95% CI: 1.5 to
16; p  0.006). Due to the rarity of mutations identified in
SCN5A
R27H
Y159X*
R43X*
S216L
W822C*
R878C
F892I*
Q1059
Q
Figure 2 Channel Topology of the Nav1.5 Pore-Forming Alpha S
and the Location of BrS-Associated Mutations
Putative pathogenic SCN5A BrS-associated mutations, absent in at least 700 Cau
and nonsynonymous functional polymorphisms are indicated by open circles. *Mu
Summary of Additional Rare Genetic Variants Identified in BrS ProbTable 3 Summary of Additional Rare Genetic Variants Identified
Gene Exon
Nucleotide
Change Mutation
No. of BrS Pati
With the Gene
Variant (N  1
SCN5A 6 647CT S216L 1
SCN5A 26 4534CT R1512W 1
CACNA1C 17 2449CT P817S 1
CACNA1C 42 5150CG A1717G 1
CACNA1C 46 5918GA R1973Q 1
CACNB2B 6 479GC S160T 2
CACNA2D1 26 2126GA S709N 2
CACNA2D1 28 2264GC S755T 1
KCNE3 1 248GA R83H 1
KCND3 3 1348CT L450F 1
SCNIBb 3A 641GA R214Q 1BrS  Brugada syndrome; ERS  early repolarization syndrome; SQTS  short QT syndrome; SIDS  sudBrS2 through BrS12 genes, we are unable to provide
genotype–phenotype correlations for these specific BrS ge-
notypes. However, none of the patients in this cohort had a
QTc interval 350 ms, which might explain the total
absence of CACNA1C-mediated BrS.
Discussion
In 2011, 2 consensus documents were published on the
diagnostic, prognostic, and therapeutic impact of genetic
testing in the clinical evaluation of cardiac channelopathies
and cardiomyopathies (20,21). For BrS, both documents
recommended genetic testing for any patient for whom
there is a clinical suspicion of BrS and emphasized the
importance of genetic testing of the index case in relation to
overall family screening. Although the HRS/EHRA expert
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hensive or (BrS1) SCN5A-targeted genetic screen “may be
useful,” the CCS/ CHRS joint position paper (20) advised
limiting BrS genetic testing to only SCN5A and to only
consider the minor genes (BrS genes 2 through 12) under
special circumstances. In addition, although the HRS/
EHRA group advised genetic testing for those patients who
fulfill the task force criteria for a clinical diagnosis of BrS,
which require an expressed type 1 Brugada ECG pattern
plus 1 or more clinical variables from the patient’s personal
or family history (such as unexplained syncope or a family
history of SCD), the CCS/CHRS group recommended
genetic testing in both clinically diagnosed BrS patients and
asymptomatic patients with only a type 1 Brugada ECG
pattern.
Drawn from the largest cohort of unrelated patients
referred for BrS genetic testing to be systematically analyzed
for mutations in the 12 known BrS-susceptibility genes (as
of June 1, 2011), there are several key observations that may
further buttress and refine these expert opinion recommen-
dations. First, our results show that there was no significant
difference in mutation detection yield between those pa-
tients who fully satisfied the clinical definition of BrS (17%)
and those patients with only a diagnostic type 1 Brugada
ECG pattern (23%), suggesting that BrS genetic testing
may be equally warranted for patients with solely an
electrocardiographic manifestation of a type 1 Brugada
ECG pattern for the main purpose of identifying probands
and their family members who should take precautionary
measures in certain conditions. This observation lends
evidence to support the CCS/CHRS position on genetic
testing of asymptomatic individuals and suggests that per-
haps the HRS/EHRA recommendation (requiring both
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Figure 3 Influence of Phenotype on
the Mutation Detection Yield
Depicted is a bar graph comparing the percentage of yield of the 8 specific
phenotypic categories showing the phenotypic effects on overall mutation yield
of our cohort. The number in each column is the number of patients with a
mutation, and the percentage of yield is given at the top of each column.
Neg.  negative; Pos.  positive; Spont.  spontaneous.abnormal findings on an electrocardiogram and personalsymptoms or family history) may be too strict. As implied in
the Canadian guidelines, a positive SCN5A genetic test
result plus a spontaneous/drug-induced type 1 Brugada
ECG pattern may be sufficient for the clinical diagnosis of
BrS. However, one must be mindful that the presence of a
positive genetic test result is not predictive of clinical
symptoms because there are pedigrees with probands that
exhibit incomplete penetrance and a lifelong asymptomatic
course. Nevertheless, if our observation is validated, then the
genetic test might become part of the diagnostic criteria
akin to the revised criteria for both arrhythmogenic right
ventricular cardiomyopathy and Marfan syndrome. Further-
more, the identification of a mutation positive subject would
at least enable the simple Brugada preventive measures of
avoiding certain drugs and reducing the degree of hyper-
thermia in the setting of febrile illnesses.
Second, whether dealing with patients with either BrS or
only a type 1 Brugada ECG pattern, the minor BrS-
susceptibility genes are indeed minor. In other words, the
sensitivity of the BrS genetic test is affected minimally by
their inclusion, lending additional merit for the option of
SCN5A (BrS1) only genetic testing rather than so-called
comprehensive, multigene BrS genetic testing. This notion
of targeted genetic testing for BrS was supported by both
guidelines as well. In addition, this study provides useful
pre-genetic test anticipatory guidance as to its pre-test
probability of returning positive results. Previously, analysis
of SCN5A among 2,000 patients, derived from 9 different
cohorts of BrS patients throughout the world, indicated an
11% to 28% yield (average  21%) for possible/probable
BrS1 status (19). Consistent with that range, the overall
yield in this study was 16.3% for SCN5A-mediated BrS (i.e.,
BrS1). However, the yield was far greater among young men
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Figure 4
Effect of Age on the Mutation
Detection Yield for the Overall, Clinically
Diagnosed, and Type 1 ECG Pattern-Only Cohorts
Depicted is a bar graph showing the percentage of yield of the 3 different age
groups (20 years of age, 20 to 40 years of age, 40 years of age) for the
overall, clinically diagnosed, and type 1 Brugada ECG pattern–only cohorts. The
number in each column is the number of patients with a mutation, and the percentage
of yield is given at the top of each column. ECG  electrocardiographic.
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those with BrS and a prolonged PQ interval. Compared
with a 10% yield for positive SCN5A test results for those
with a PQ interval 200 ms, the yield was almost 40%
when the PQ interval 200 ms. This is consistent with
previous observations that SCN5A-positive BrS patients
displayed prolonged HV and PQ intervals during electro-
physiology study (30,31).
Finally, in the absence of a short QT interval, calcium
channel–mediated BrS is extremely uncommon. Here, mu-
tations in genes encoding the alpha1 (CACNA1C), beta2
(CACNB2B), and alpha2delta1 (CACNA2D1) were ob-
served in 2% of this cohort. In contrast, perturbations
involving the calcium channel macromolecular complex
were implicated as the second most common genetic cause
of BrS, accounting for 12% of the disease, and as much as
18% when including rare polymorphisms (9). A close
examination of those seminal discoveries underscores the
tight link between calcium channel–mediated disease and
the clinical phenotype of BrS with a concomitant short QT
interval, in which 50% of patients with BrS/short QT
interval hosted a mutation in an L-type calcium channel
ubunit (9). Once again, this illustrates the critical impor-
ance of the phenotypic classification and the opportunity
or phenotype-guided genetic testing within what is cur-
ently captured under the header of BrS. Given the in-
reased recognition of so-called background genetic noise or
otential false-positive results with respect to genetic testing
or heritable arrhythmias and/or cardiomyopathic syndromes
25,32), phenotype-targeted testing within the spectrum of
-wave syndromes may minimally compromise the test’s sen-
itivity while significantly enhancing its specificity. Just like an
CN5A-centric genetic test for classic BrS, especially with
oncomitant PQ interval prolongation, these data would sug-
est similar consideration for primary genetic testing of the
enes that encode the calcium channel’s pore-forming subunit
nd its auxiliary subunits rather than SCN5A, for the ECG
henotype of type 1 Brugada ECG pattern with concomitant
hort QT intervals.
tudy limitations. There are 2 major limitations of this
tudy, one dealing with the veracity of the phenotype and
he other dealing with the certainty of the genotype.
lthough the ECG phenotype was vetted for every one of
he patients in this study by at least 1 of the authors, not
very patient in this study was evaluated clinically by the
uthors because our study population consisted of patients
eferred to our laboratories for genetic testing. Accordingly,
or the 83 patients with only a type 1 Brugada ECG pattern,
ecause we did not personally ask the questions to elicit the
istory for every patient in our cohort, we do not know that
he personal and family history was indeed negative. How-
ver, this potential failure to elicit the clinical information is
nlikely because 1 of the coauthors (L.C.) directly evaluated
80% of the patients in this cohort, and the same referring
hysicians submitted patients with detailed characterization
f positive symptomatology. With respect to the genotype,he major limitation of this study pertains to the issue of
utation calling (19,24,25). None of the 15 novel muta-
ions reported in this study cohort have been characterized
unctionally. Instead, strict absence from our internal set of
thnic-matched reference alleles and all available online
atabases, including the 1000 Human Genome Project
atabase (23), was required. Despite this stringent bar to
stablish rarity (i.e., not seen in 3,000 reference alleles), it
s possible that some of these variants listed as putative
athogenic mutations may be innocuous functionally. Con-
ersely, this strict “absence from all controls” definition may
ave resulted in the exclusion of other variants that are
evertheless disease contributing. S216L-SCN5A and
R1512W-SCN5A illustrate this possibility. In vitro expres-
sion of S216L-SCN5A channels was associated with a 60%
reduction in peak sodium current and moderate slowing of
inactivation (26). Similarly, in vitro studies of R1512W-
SCN5A demonstrated slower inactivation and recovery from
inactivation consistent with a loss-of-function phenotype
anticipated for BrS1 mutations (27). However, both S216L
and R1512W have been previously reported in ostensibly
healthy controls. Assignment of a given variant’s pathogenic-
ity is a vexing problem and has been declared the Achilles’ heel
of genetic testing (21,25,33). This issue underscores the critical
need to align carefully the phenotype with the appropriate
genetic test panel that best balances the sensitivity/specificity
issue rather than simply continuing to add the next novel
disease-susceptibility gene.
Conclusions
To our knowledge, this study is the first comprehensive
mutational analysis of all 12 BrS-susceptibility genes dis-
covered to date for a single large cohort of BrS patients.
SCN5A-mediated BrS (BrS1) is still the only common
genetic substrate for BrS in general, particularly for young
male BrS patients (20 years) and those BrS patients with
a PQ interval  200 ms who may have a 40% to 50%
pre-test probability for a positive SCN5A genetic test result.
In addition, our data suggest that both clinically diagnosed BrS
patients and patients presenting with only a spontaneous/drug-
induced type 1 Brugada ECG pattern may equally warrant
SCN5A genetic testing. Finally, the other 11 BrS genes
account for 5% of our cases, and in the absence of BrS plus
a short QT interval, calcium channel–mediated BrS is very
uncommon, far less than the initial 10% to 15% estimates.
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